Duration of anticoagulant therapy for patients with venous thromboembolism

Thrombosis Research

Volumn 123, Issue SUPPL. 1, 2008, Pages

  Garcia, David ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

D DIMER; DALTEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DEEP VEIN THROMBOSIS; HUMAN; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; THROMBOPHILIA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; FEMALE; HEMORRHAGE; HUMANS; MALE; RECURRENCE; RISK FACTORS; SEX CHARACTERISTICS; THROMBOPHILIA; TIME FACTORS; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 55249114340     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.08.019     Document Type: Article

References (23)

1. Kearon C., Gent M., Hirsh J., Weitz J., Kovacs M.J., Anderson D.R., et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340 12 (Mar 25 1999) 901-907
2. Ridker P.M., Goldhaber S.Z., Danielson E., Rosenberg Y., Eby C.S., Deitcher S.R., et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.[comment]. N Engl J Med 348 15 (04/10/ 2003) 1425-1434
3. Agnelli G., Prandoni P., Santamaria M.G., Bagatella P., Iorio A., Bazzan M., et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 345 3 (Jul 19 2001) 165-169
4. Baglin T., Luddington R., Brown K., and Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 362 9383 (Aug 16 2003) 523-526
5. Hull R.D., Pineo G.F., Brant R.F., Mah A.F., Burke N., Dear R., et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119 12 (Dec 2006) 1062-1072
6. Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 2 (07/10/ 2003) 146-153
7. Palareti G., Cosmi B., Legnani C., Tosetto A., Brusi C., Iorio A., et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 355 17 (Oct 26 2006) 1780-1789
8. Baglin T., Palmer C.R., Luddington R., and Baglin C. Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors. J Thromb Haemost 6 4 (Apr 2008) 577-582
9. Baglin T., Luddington R., Brown K., and Baglin C. High risk of recurrent venous thromboembolism in men. J Thromb Haemost 2 12 (Dec 2004) 2152-2155
10. Kyrle P.A., Minar E., Bialonczyk C., Hirschl M., Weltermann A., and Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 350 25 (Jun 17 2004) 2558-2563
11. McRae S., Tran H., Schulman S., Ginsberg J., and Kearon C. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 368 9533 (Jul 29 2006) 371-378
12. Kearon C., Ginsberg J.S., Kovacs M.J., Anderson D.R., Wells P., Julian J.A., et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349 7 (08/14/ 2003) 631-639
13. Christiansen S.C., Cannegieter S.C., Koster T., Vandenbroucke J.P., and Rosendaal F.R. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 293 19 (May 18 2005) 2352-2361
14. Schulman S., Svenungsson E., and Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 104 4 (Apr 1998) 332-338
15. Linkins L.A., Choi P.T., and Douketis J.D. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 139 11 (Dec 2 2003) 893-900
16. Douketis J.D., Gu C.S., Schulman S., Ghirarduzzi A., Pengo V., and Prandoni P. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med 147 11 (Dec 4 2007) 766-774
17. Wysowski D.K., Nourjah P., and Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 167 13 (Jul 9 2007) 1414-1419
18. Kuijer P.M., Hutten B.A., Prins M.H., and Buller H.R. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 159 5 (Mar 8 1999) 457-460
19. Shireman T.I., Mahnken J.D., Howard P.A., Kresowik T.F., Hou Q., and Ellerbeck E.F. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 130 5 (Nov 2006) 1390-1396
20. Beyth R.J., Quinn L., and Landefeld C.S. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med 133 9 (Nov 7 2000) 687-695
21. Landefeld C.S., and Beyth R.J. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 95 3 (Sep 1993) 315-328
22. Schulman S., Granqvist S., Holmstrom M., Carlsson A., Lindmarker P., Nicol P., et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 336 6 (1997) 393-398
23. Connolly S., Pogue J., Hart R., Pfeffer M., Hohnloser S., Chrolavicius S., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367 9526 (Jun 10 2006) 1903-1912